Octapharma welcomes marketing approval for Octaplas

Octapharma has welcomed the approval for marketing of its Octaplas product in various countries around Europe, including the UK.

The product can be used in place of plasma during blood transfusions and is claimed to be “virtually free” of properties that might causing allergic reactions among patients.

Furthermore, the product is also said to be free from any ingredients that could instigate an instance of acute lung injury, which is the most common cause of death among patients undergoing a transfusion.

A statement from Octapharma explained: “Octaplas is fully licensed in 29 countries worldwide, and roughly six million bags have been used successfully to treat approximately two million patients around the world since 1991.”

Octapharma is based in Switzerland and has operations around the world.

The company specialises in developing and marketing plasma fractionation products and all kinds of plasma derivatives.